Dr. Markus Rimann

Dr. Markus Rimann

Dr. Markus Rimann
ZHAW Life Sciences und Facility Management
Einsiedlerstrasse 31
8820 Wädenswil

+41 (0) 58 934 55 12
markus.rimann@zhaw.ch

Persönliches Profil

Tätigkeit an der ZHAW als

Group Leader 3D Tissues and Biofabrication
3D Bioprinting
Development of novel biomaterials
Tissue Engineering
Automated Systems
Competence Centre TEDD (Tissue Engineering for Drug Devlopment and Substance Testing)

www.zhaw.ch/icbt/3d-tissues-and-biofabrication/

Arbeits- und Forschungsschwerpunkte, Spezialkenntnisse

Bioprinting
Development of printable biomaterials (bioinks)
3D cell culture models for drug development and substance testing

Aus- und Fortbildung

Markus Rimann completed his degree in Biology, specialty in Biotechnology, at the ETH Zurich in 2005. As a PhD student he was developing a somatic gene therapy approach to improve cutaneous wound healing. He received his Dr. sc. nat. from the ETH Zurich in 2009. As postdoc at the Center for Applied Biotechnology and Molecular Medicine (CABMM) at the University of Zurich he was focusing on the usage and tracking of mesenchymal stem cells (MSCs) for the treatment of osteoporosis. Since 2011, he works at the Zurich University of Applied Sciences (ZHAW) in the Tissue Engineering team of Prof. Dr. Graf-Hausner. He was involved in initiating the TEDD (Tissue Engineering for Drug Development and Substance Testing) Competence Centre. The TEDD network is a collaborative innovation platform, dedicated to 3D cell culture te¬chnology and organ-like tissue models for drug development, substance testing, personalized and re-generative medicine. The network pools and transfers knowledge and technologies by combining diverse skills through integrative cooperation among academic, clinical and industrial partners. He works with different 3D cell culture systems with or without scaffolds. His research is mainly application-driven to make organotypic model systems available for industry as well as for the clinics. The main focus is on developing 3D cell models for substance testing including automated production, maintenance and analysis. In an approach for personalized medicine osteosarcoma microtissues from patient-derived material were produced and subjected to drug treatment to determine in the future best cancer treatment options. With a scaffold-based cell culture system the entire process of cell encapsulation, maintenance, drug application and viability measurements was automated on a liquid-handling robot to demonstrate HTS-compatibility. As a group leader, he is interested in the further development of the promising bioprinting technology. In different industry projects several tissue models were printed: i) full-thickness skin model for the cosmetic industry to assess harmlessness of cosmetic ingredients, ii) muscle/tendon tissues in a novel 24 well plate for the pharma industry to find new therapeutic treatments for muscle-related diseases, and a kidney model (proximal tubulus of the nephron) to assess nephrotoxicity of drugs. In order to provide suitable bioinks the group is developing printable and cell compatible materials (hydrogels).

Mitglied in Netzwerken

Projekte

Mitarbeit an folgenden Projekten

Publikationen

Beiträge, peer-reviewed

; ; ; ; ().

Standardized 3D bioprinting of soft tissue models with human primary cells

.

Journal of Laboratory Automation DOI: 10.1177/2211068214567146. Peer reviewed.

; ; ; ; ; ; ().

An in vitro osteosarcoma 3D microtissue model for drug development

.

Journal of Biotechnology, 189 129-135. Peer reviewed.

; ; ; ; ().

Automation of 3D cell culture using chemically defined hydrogels

.

Journal of Laboratory Automation, 19, 2. 191-197. Peer reviewed.

; ; ; ; ().

TEDD - innovation network for 3D cell cultivation. 3D cell culture for drug development

.

Chimia, 67, 11. 822-824. Peer reviewed.

; ().

Synthetic 3D multicellular systems for drug development

.

Current Opinion in Biotechnology , 23. 1-7. Peer reviewed.

Beiträge, nicht peer-reviewed

; ; ; ; ; ; ; ; ; ().

3D bioprinted tissue models for substance testing

: Oral presentation.

SLAS 2017, Congress, Washington DC, USA.

; ; ().

Bioresorbable polymers for bioprinting applications

: Book chapter.

Bioresorbable polymers for biomedical application 331-362.

; ; ; ; ; ; ; ; ().

3D models for compound testing

: Oral presentation.

3D models and drug screening, Congress, Berlin, D.

; ; ; ; ; ; ; ; ().

3D tissue models - new perspectives in medicine

: Oral presentation.

CLINAM, Congress, Basel.

().

3D tissues and biofabrication for therapy and industrial applications

: Oral presentation.

Spiez CONVERGENCE, Workshop, Spiez.

; ; ; ; ; ; ; ; ; ; ; ; ; ().

A novel multiwell device for drug development with bioprinted 3D human tendon and skeletal muscle tissues

.

Science Slam and Poster presentation. In: CTI Swiss Medtech Day 2016. Congress. Bern: Swiss Confederation.

; ; ; ; ; ; ; ; ; ; ; ; ; ; ().

A novel multiwell device for drug development with bioprinted 3D human tendon and skeletal muscle tissues

: Poster presentation.

Swiss Medtech Day 2016, Congress, Bern.

; ; ; ; ().

Bioprinted kidney model for nephrotoxicity assessment

: Poster presentation.

Swiss Medtech Day 2016, Congress, Bern.

; ; ; ; ; ; ; ; ().

Bioprinted tissue models for substance evalution

: Oral presentation.

Basel Life Science Week 2016, Congress, Basel.

; ; ; ; ; ; ; ; ; ().

Bioprinted tissues for substance evaluation

: Oral presentation.

Biointerfaces International, Congress, Zurich.

; ; ; ; ; ; ; ().

Bioprinted tissues for substance testing

: Oral presentation.

In: 3D Cell Culture 2016: How close to 'in vivo' can we get? Models, applications & translation. Kongress. Freiburg: Dechema.

; ; ; ; ; ; ().

Standardized 3D bioprinting of skin models for drug development

: Oral presentation.

In: 4th International Cosmetic Innovation Days ‘Cosminnov’. Kongress. Orleans: Atera.

; ; ; ().

Zurich University of Applied Sciences, Center for Cell Biology and Tissue Engineering

: Poster presentation.

Roche Symposium, Basel.

; ; ; ; ; ; ; ; ; ; ; ; ; ; ().

A novel multiwell device for drug development with bioprinted 3D human tendon and skeletal muscle tissues

: Poster presentation.

In: CTI Medtech Event. Kongress. Bern: Swiss Confederation.

; ; ; ; ; ; ; ; ().

Bioprinted muscle/tendon for drug assessment

: Poster presentation.

NTN Innovationday, Congress, Zug.

; ; ; ; ; ().

Bioprinted sof tissue models for compound testing

: Oral presentation.

Biofabrication , Congress, Utrecht, NL.

().

Bioprinting: Break-Out Session

: Oral presentation.

Expert forum on 3D printing, Swiss Re, Forum, Rüschlikon.

; ; ; ; ; ; ; ; ().

Soft tissue bioprinting in tissue engineering for drug development

: Oral presentation.

Oltenmeeting, biotechnet, Congress, Olten.

; ().

Tissue bioprinting for compound evaluation

: Oral presentation, Nominee for Swiss Medtech Award.

CTI Medtech Event, Congress, Bern.

().

3D cell-based assays for drug de-risking

.

SLAS Short course, Oral presentation, September. Basel.

().

A 3D osteosarcoma model

.

Wissenschaftliches Forum über "Challenges and opportunities in the development of novel anti-tumor therapies", Oral presentation, September. Schlieren.

; ; ; ; ; ; ; ; ; ; ; ; ; ; ().

A novel multiwell device for drug development with bioprinted 3D human tendon and skeletal muscle tissues

: Poster presentation.

In: CTI Medtech Event 2014. Kongress. Bern: Swiss Confederation.

().

Additive Verfahren mit biologischen Materialien

.

3D Druck und Healthtech, Healthtech Cluster Switzerland, Oral presentation, August. Küssnacht am Rigi.

; ; ; ; ; ; ; ; ().

Aktuelle Trends bei der in vitro-Substanztestung in Deutschland und in der Schweiz

.

BIOspektrum 470-472.

().

Bioprinting von 3D Gewebemodellen

.

5. Kongress: Industrielle Zelltechnik, Oral presentation, September. Lübeck (D).

().

Bioprinting: Aktueller Stand in der Forschung

.

3D Druck: Revolution in Technik, Recht und Medizin? Stiftung Risiko-Dialog, Oral presentation, August. Winterthur.

().

Competence Centre TEDD Tissue Engineering for Drug Development

.

Oral presentation, Swiss Soft Days, Symposium. 6. June.

; ; ; ; ; ; ().

Human 3D osteosarcoma models for drug testing

.

Oral presentation, 3D cell culture symposium, Dechema. Freiburg (D).

; ; ; ; ; ; ; ; ().

Skin bioprinting: an approach to produce standardized skin models on demand

: Oral Presentation.

In: Dechema 3D Cell Culture 2014. Kongress. Freiburg: Dechema.

; ; ; ; ; ; ; ; ().

Skin bioprinting: an innovative approach to produce standardized skin models on demand

: Poster.

In: Swiss BiotechTM Innovation Day 2014. Kongress. (28 August). Basel: Swiss Biotech.

().

Automation of 3D cell cultures using defined biomimetic hydrogels

.

Oral presentation, FAST Congress, Boston, USA. October.

; ; ; ; ; ; ; ().

Skin bioprinting: an innovative approach to produce standardized skin models on demand

.

Poster presentation, CTI Medtech Event 2013, 27. August.

; ; ; ; ().

Cryopreservation of spherical tumor microtissues

: Poster presentation.

In: 3D cell culture. Congress. (14-16. March). Zurich: Dechema Biotechnologie.

; ; ; ; ; ; ().

Organomimetic skin model production based on a novel bioprinting technology

: Oral presentation.

In: 3D cell culture. Congress. (16. March). Zurich: Dechema Biotechnologie.

; ; ; ; ; ; ; ().

Skin bioprinting: an innovative approach to produce standardized skin models on demand

.

Poster presentation, CTI Medtech Event 2012, (24. September.

; ; ; ; ; ; ().

Organomimetic skin model production based on a novel bioprinting technology

: Poster presentation.

In: CTI Medtech Event 2011. Congress. (23. August). Bern: Swiss confederation.